- Takeda's TIDES trial confirms QDENGA's efficacy and safety over 7 years.
- QDENGA's two-dose regimen shows 61.2% efficacy, increasing to 74.3% with a booster.
- The vaccine is approved in 41 countries, with 18.6 million doses distributed.
- QDENGA is effective against all four dengue virus serotypes with no new safety signals.
Study Findings
Takeda's TIDES trial confirms the long-term safety and efficacy of the dengue vaccine QDENGA over a 7-year period. The two-dose regimen provides sustained protection, with a vaccine efficacy (VE) of 61.2% in preventing virologically confirmed dengue, increasing to 74.3% with a booster dose.
Global Impact
QDENGA is the longest-studied dengue vaccine and the only one approved for use regardless of prior disease exposure. It has been authorized in 41 countries, with 18.6 million doses distributed across 11 endemic countries. The vaccine has shown 84.1% VE in preventing dengue-related hospitalizations, which increases to 90.6% after a booster dose.
Public Health Significance
The inclusion of QDENGA in Brazil's public vaccination program has significantly reduced symptomatic dengue cases and hospitalizations. The vaccine's efficacy is consistent across all four dengue virus serotypes, with no new safety signals observed following the administration of a booster dose.
Ongoing Research
Takeda continues to invest in post-marketing research to further understand the vaccine's safety and impact. This includes an Impact Study in Dourados, Brazil, and the DEN-401 study in Southeast Asia. The World Health Organization has added QDENGA to its List of Prequalified Vaccines, underscoring its quality and suitability for public vaccination programs.
